Sequential antimicrobial therapy - The role of quinolones

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue 4, 1997, Pages 441-446

  Nathwani, Dilip ^a   Tillotson, Glen ^b   Davey, Peter ^c  

^a King's Cross Hospital   (United Kingdom)

^b BAYER CORPORATION   (United States)

^c UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFIXIME; CEFOTAXIME; CEFTAZIDIME; CEFUROXIME AXETIL; CIPROFLOXACIN; CLINDAMYCIN; ERYTHROMYCIN; FAMCICLOVIR; FLUCLOXACILLIN; FLUCONAZOLE; METRONIDAZOLE; OFLOXACIN; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIMICROBIAL THERAPY; COST CONTROL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTI-INFECTIVE AGENTS; CLINICAL TRIALS; COSTS AND COST ANALYSIS; HUMANS; INJECTIONS, INTRAVENOUS; META-ANALYSIS; QUINOLONES; UNITED STATES;

EID: 0030975692     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (54)

1. Col, N. F. & O'Connor, R. W. (1987). Estimating worldwide current antibiotic usage: report of Task Force 1. Reviews of Infectious Diseases 9, Suppl. 3, S232-43.
2. Barrière, S. L. (1985). Cost containment of antimicrobial therapy. Drug Intelligence and Clinical Pharmacy 19, 278-81.
3. Kunin, C. M., Tupasi, T. & Craig, W. A. (1973). Use of antibiotics: a brief exposition of the problem and some tentative solutions. Annals of Internal Medicine 79, 555-60.
4. Maki, D. G. & Schuna, A. A. (1978). A study of antimicrobial misuse in a university hospital. American Journal of the Medical Sciences275, 271-82.
5. Gould, I. M. (1988). Control of antibiotic use in the United kingdom. Journal of Antimicrobial Chemotherapy 22, 395-7.
6. Working Party of the British Society for Antimicrobial Chemotherapy. (1994). Hospital antibiotic control measures in the UK. Journal of Antimicrobial Chemotherapy 34, 21-42.
7. Mandell, L. A., Bergeron, M. G., Gribble, M. J., Jewesson, P. J., Low, D. E., Marrie, T. J. et al. (1995). Sequential antibiotic therapy: effective cost management and patient care. Canadian Journal of Infectious Diseases 6, 306-15.
8. Quintillani, R. & Nightingale, C. (1994). Transitional antibiotic therapy. Infectious Diseases in Clinical Practice 3, Suppl. 3, S161-6.
9. Guay, D. R. P. (1993). Sequential antimicrobial therapy. A realistic containment. Pharmacoeconomics 3, 341-4.
10. Quintiliani, R., Cooper, B. W., Briceland, L. L & Nightingale, C. H. (1987). Economic impact of streamlining antibiotic administration. American Journal of Medicine 82, Suppl. 4A, 391
11. Jewesson, P. (1994). Cost-effectiveness and value of an iv switch. Pharmacoeconomics 5, Suppl. 2, 20-6.
12. Janknegt, R. & van der Meer, J. W. M. (1994). Sequential therapy with intravenous and oral cephalosporins. Journal of Antimicrobial Chemotherapy 33, 169-77.
13. Chayakul, P., Krisanapan, S. & Kalnauwakul, S. (1993). Sequential intravenous/oral ciprofloxacin in the treatment of severe multi-resistant Gram-negative infections. Journal of the Medical Association of Thailand 76, 35-40.
14. Balinsky, W. & Nesbitt, S. (1989). Cost-effectiveness of outpatient parenteral antibiotics: a review of the literature. (1989). American Journal of Medicine 87, 301-5.
15. Williams, D. N. (1995). Home intravenous antibiotic therapy (HIVAT): indications, patients and antimicrobial agents. International Journal of Antimicrobial Agents 5, 3-8.
16. Nathwani, D. (1995). New options in the treatment of serious and chronic infections. Hospital Update 21, 2-3.
17. Milkovich, G. (1995). Benefits of outpatient parenteral antibiotic therapy: to the individual, the institution, third-party payers and society. International Journal of Antimicrobial Agents 5, 27-31.
18. Thickson, N. D. (1993). Economics of home intravenous services. Pharmacoeconomics 3, 220-7.
19. Bartlett, J. G. (1995). Impact of new oral antibiotics on the treatment of infectious diseases. Infectious Diseases in Clinical Practices 4, Suppl. 2, S50-7.
20. Parker, S. E. & Davey, P. G. (1992). Pharmacoeconomics of intravenous drug administration. Pharmacoeconomics 1, 103-15.
21. Birdwell, S. W. (1993). Direct costs of intravenous delivery systems. Pharmacoeconomics 4, 8-13.
22. Collignon, P. (J. 1994). Australian Study on Intravascular Catheter Associated Sepsis. Intravascular catheter associated sepsis: a common problem. Medical Journal of Australia 161, 374-8.
23. Lamount, C. T., Sampson, S., Matthias, R. & Kane, R. (1983). The outcome of hospitalisation for acute illness in the elderly. Journal of the American Geriatric Society 31, 282-8.
24. Leape, L. L., Brennan, T. A., Laird, N., Lawthers, A. G., Localio, A. R., Barnes, B. A. et al. (1991). The nature of adverse events in hospitalised patients: results of the Harvard Medical Practice Study II. New England Journal of Medicine 324, 377-84.
25. Alien, B., Naismith, N. W., Manser, A. J. & Moulds, R, F. W. (1992). A campaign to improve the timing of conversion from intravenous to oral administration of antibiotics. Australian Journal of Hospital Pharmacy 22, 434-9.
26. Frighetto, L., Nickoloff, D., Martinusen, S. M., Mamdani, F. S. & Jewesson, P. J. (1992). Intravenous-to-oral stepdown program: four years of experience in a large teaching hospital. Annals of Pharmacotherapy 26, 1447-51.
27. Cooke, J., Cairns, C. J., Tillotson, G. S., Conner, S., Lewin, S. K., Nicholls, J. et al. (1993). Comparative clinical, microbiologic, and economic audit of the use of oral ciprofloxacin and parenteral antimicrobials. Annals of Pharmacotherapy 27, 785-9.
28. Barrière, S. L. (1987). Economic impact of oral ciprofloxacin: a pharmacist's perspective. American Journal of Medicine 82, Suppl. 4A, 387-90.
29. Fliegelman, R. M., Mattingly, P. M., Dempsey, C. L. & Sokalski, S. J. (1990). Economic impact of oral ciprofloxacin following standard intravenous therapy. Diagnostic Microbiology and Infectious Diseases 13, 187-9.
30. Paladino, J. A., Sperry, H. E., Backes, J. M., Gelber, J. A., Serrianne, D. J., Gumbo, T. J. et al. (1991). Clinical and economic I evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. American Journal of Medicine 91, 462-70.
31. Grasela, T. H., Paladino, J. A., Schentag, J. J., Heupenbecker, D., Rybacki, J., Purcell, J. B. et al. (1991). Clinical and economic impact of oral ciprofloxacin as follow-up to parenteral antibiotics. DICP-Annals of Pharmacotherapy 25, 857-62.
32. Cramer, J. A., Mattson, R. H., Prevey, M. L., Scheyer, R. D. & Oullette, V. L. (1989). How often is medication taken as prescribed? Journal of the American Medical Association 261, 3273-7.
33. Anon. (1993). Antibiotic drug interactions. Drug Interactions Update 13, 199-284.
34. Craig, W. A. & Andes, D. R. (1995). Parenteral versus oral antibiotic therapy. Medical Clinics of North America 79, 497-508.
35. McMaster University Health Sciences Centre. (1981). How to read clinical journals. V: To distinguish useful from useless or even harmful therapy. Canadian Medical Association Journal 124, 1156-62.
36. Dominguez, J., Palma, F., Vega, M. E., Magana, J. L., Ortiz, G., Teresa-Hojyo, M. et al. (1989). Prospective, controlled, randomized non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of skin or softtissue infections. American Journal of Medicine 87, Suppl. 5A, 136S-7S.
37. Cox, C. E. (1989). Sequential intravenous and oral ciprofloxacin versus intravenous ceftazidime in the treatment of complicated urinary tract infections. American Journal of Medicine 87, Suppl. 54, 157S-9S.
38. Gangji, D., Jacobs, F., de Jonckheer, J., Coppens, L., Serruys, E., Hanotte, F. et al. (1989). Randomized study of intravenous versus intravenous/oral regimen of ciprofloxacin in the treatment of Gram-negative septicemia. American Journal of Medicine 87, Suppl. 5A, 206S-8S.
39. Gaut, P. L., Carron, W. C., Ching, W. T. W. & Meyer, R. D. (1989). Intravenous/oral ciprofloxacin therapy versus ceftazidime therapy for selected bacterial infections. American Journal of Medicine 87, Suppl. 5A, 169S-75S.
40. Fass, R. J., Plouffe, J. F. & Russell, J. A. (1989). Intravenous/oral ciprofloxacin therapy versus ceftazidime in the treatment of serious infections. American Journal of Medicine 87, Suppl.5A, 164S-8S.
41. Kalager, T., Andersen, B. M., Bergan, T., Brubakk, O., Bruun, J. N., Doskeland, B. et al. (1992). Ciprofloxacin versus tobramcyin/ cefuroxime combination in the treatment of serious systemic infections: a prospective, randomized and controlled study of efficacy and safety. Scandinavian Journal of Infectious Diseases 24, 637-46.
42. Smith, M. D., Duong, N. M., Hoa, N. T. T., Wain, J., Ha, H. D., Diep, T. S. et al. (1994). Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever. Antimicrobial Agents and Chemotherapy 38, 1716-20.
43. Pippalla, R. S., Riley, D. A. & Chinburapa, V. (1995). Influencing the prescribing behaviour of physicians: a metaevaluation. Journal of Clinical Pharmacy and Therapeutics 20, 189-98.
44. Pilley, G. (1989). Cost comparison of ciprofloxacin versus cefamandole. Annals of Pharmacotherapy 23, 92-3.
45. Frieden, T. R. & Mangi, R. J. (1990). Inappropriate use of oral ciprofloxacin. DlCP-Journal of the American Medical Association 264, 1438-40.
46. Adu, A., Donovan, B., Newgham, C. & Armour, C. (1994). Ciprofloxacin usage in a community hospital. Australian Journal of Hospital Pharmacy 24, 318-22.
47. Pickering, T. D., Gurwitz, J. H., Zaleznik, D., Noonan, J. P. & Avorn, J. (1994). The approprlateness of oral fluoroquinolone-prescribing in the long-term care setting. Journal of the American Geriatrics Society 42, 28-32.
48. Spiers, G. E., Fenelon, L. E., Reeves, D. S., Speller, D. C. E., Smyth, E. G., Wilcox, M. H. et al. (1995). An audit of Ciprofloxacin use in a district general hospital. Journal of Antimicrobial Chemotherapy 36, 201-7.
49. Solomkin, J. S., Reinhart, H. H., Dellinger, E. P., Bohnen, J. M., Rotstein, O. D., Vogel, S. B. etal. (1996). Results of a randomized trial comparing sequential intravenous oral treatment with Ciprofloxacin plus metronidazole to imipenem/cilastatin for intraabdominal infections. Annals of Surgery 223, 303-15.
50. Cohn, S. M., Cohn, K. A., Rafferty, M. J., Smith, A. H., Degutis, L. C., Kowalsky, S. F., etal. (1995). Enteric absorption of Ciprofloxacin during the immediate postoperative period. Journal of Antimicrobial Chemotherapy 36, 717-21.
51. Kreling, D. H. & Mott, D. A. (1993). The cost effectiveness of drug utilization: review in an outpatient setting. Pharmacoeconomics 4, 414-36.
52. Davey, P. G., Parker, S. E., Orange, G., Malek, M. & Dodd, T. (1995). Prospective audit of costs and outcome of aminoglycoside treatment and of therapy for Gram-negative bacteraemia. Journal of Antimicrobial Chemotherapy 36, 561-75.
53. Hamilton-Miller, J. M. T. (1996) Switch therapy: the theory and practice of early change from parenteral to non-parenteral antibiotic administration. Clinical Microbiology and Infectious Diseases 2, 12-20.
54. Campoli-Richards, D. M., Monk, J. P., Price, A., Benfield, P., Todd, P. A. & Ward, A. (1988). Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 35, 373-447.